Young Lung Cancer Initiative Podcast

They Told Me "No" (How I got Surgery Anyway) : Jessie's EGFR Lung Cancer Story | Pt 3/3

"I completely deflated." When Jessie was told she was "not a candidate" for surgery to remove her primary lung tumor (the "mothership"), she didn't just accept the answer. As a professional producer, she did what she does best: she assembled an "A-Team" of the world’s leading experts to find a path forward. In this powerful conclusion to our three-part series, Jessie shares the "sobering conversations," the medical disagreements, and the path that eventually led her to a successful surgery. ⚠️ Disclaimer This content is for informational purposes only and is not medical advice. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition. Chapters 00:00 [https://www.youtube.com/watch?v=PzsjykpmCFE&list=PLA6NQl_P42YP5ifM57e5ZWprqXmbr2OaI&index=4] Introduction 00:23 [https://www.youtube.com/watch?v=PzsjykpmCFE&list=PLA6NQl_P42YP5ifM57e5ZWprqXmbr2OaI&index=4&t=23s] Assembling a Care Team 01:40 [https://www.youtube.com/watch?v=PzsjykpmCFE&list=PLA6NQl_P42YP5ifM57e5ZWprqXmbr2OaI&index=4&t=100s] Navigating Treatment Options 05:17 [https://www.youtube.com/watch?v=PzsjykpmCFE&list=PLA6NQl_P42YP5ifM57e5ZWprqXmbr2OaI&index=4&t=317s] The Role of Advocacy in Care 06:53 [https://www.youtube.com/watch?v=PzsjykpmCFE&list=PLA6NQl_P42YP5ifM57e5ZWprqXmbr2OaI&index=4&t=413s] Hope for the Future of Lung Cancer Treatment Thank you to Johnson & Johnson for supporting this series. 📢 Amplifying the Voices of Young-Onset Lung Cancer Lung cancer is often caught late in young adults because "they're too young." At the Young Lung Cancer Initiative (YLCI), we are changing that narrative. We are a 501(c)(3) nonprofit dedicated to providing support, research, and advocacy for the young-onset community. New here? Hit SUBSCRIBE to help us share these stories and ensure no young person faces this diagnosis alone. 💙 Learn More 🌐 Visit Our Website: https://ylci.org/ [https://ylci.org/] 📱 Connect With Us Instagram— @younglungcancer

"Less cancer today than yesterday" - Jessie's Parenting Approach with EGFR Lung Cancer| Pt 2/3

"My five-year-old asked if he could watch a show now. My middle daughter wanted to know how this cancer was different from everyone else's." In Part 2 of this 3-part series, Jessie and Leah go deeper into what it actually looks like to live with Stage 4 EGFR mutant non-small cell lung cancer. Jessie walks through how she told her three kids about her diagnosis. She and Leah discuss the caregiving burden that nobody talks about. Chapters: 00:00 [https://www.youtube.com/watch?v=xF43XEXRImc&list=PLA6NQl_P42YP5ifM57e5ZWprqXmbr2OaI&index=1] Introduction 00:47 [https://www.youtube.com/watch?v=xF43XEXRImc&list=PLA6NQl_P42YP5ifM57e5ZWprqXmbr2OaI&index=1&t=47s] Telling the Kids 02:30 [https://www.youtube.com/watch?v=xF43XEXRImc&list=PLA6NQl_P42YP5ifM57e5ZWprqXmbr2OaI&index=1&t=150s] Three Kids, Three Completely Different Reactions 04:15 [https://www.youtube.com/watch?v=xF43XEXRImc&list=PLA6NQl_P42YP5ifM57e5ZWprqXmbr2OaI&index=1&t=255s] Following Each Other's Lead: The Caregiver Experience 06:45 [https://www.youtube.com/watch?v=xF43XEXRImc&list=PLA6NQl_P42YP5ifM57e5ZWprqXmbr2OaI&index=1&t=405s] "A Picture of My Brain, Just to Make Sure It's Still Smiling" 07:30 [https://www.youtube.com/watch?v=xF43XEXRImc&list=PLA6NQl_P42YP5ifM57e5ZWprqXmbr2OaI&index=1&t=450s] Keeping the Conversation Evolving as Kids Get Older Thank you to Johnson & Johnson for supporting this series. ⚠️ Disclaimer This content is for informational purposes only and is not medical advice. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition. #lungcancer [https://www.youtube.com/hashtag/lungcancer] #patient [https://www.youtube.com/hashtag/patient] #egfr [https://www.youtube.com/hashtag/egfr] 📢 Amplifying the Voices of Young-Onset Lung Cancer Lung cancer is often caught late in young adults because "they're too young." At the Young Lung Cancer Initiative (YLCI), we are changing that narrative. We are a 501(c)(3) nonprofit dedicated to providing support, research, and advocacy for the young-onset community. New here? Hit SUBSCRIBE to help us share these stories and ensure no young person faces this diagnosis alone. 💙 Learn More 🌐 Visit Our Website: https://ylci.org/ [https://ylci.org/] 📱 Connect With Us Instagram— @younglungcancer

From Panic Attacks to Stage IV: Jessie's EGFR lung cancer story | Pt 1/3

Jessie was 42 when she was diagnosed with stage IV EGFR non-small cell lung cancer but her symptoms had been dismissed for nearly a year. Night sweats, panic attacks, a pneumonia that never fully resolved, and a cough that just wouldn't quit. It wasn't until November that a pulmonologist finally told her, "We should have given you a bronchoscopy yesterday." What followed was five days that changed everything. In this first episode, Jessie talks about the year of symptoms that almost got written off, the week of her diagnosis, what it felt like to collapse on the sidewalk not knowing if she'd see her kids grow up, and what happened when she finally found out her cancer was targetable. This series is sponsored by Johnson & Johnson. About Young Lung Cancer Initiative (YLCI). YLCI is a 501(c)(3) nonprofit dedicated to the young-onset community. We provide support, research, and advocacy to ensure that no young person faces a lung cancer diagnosis alone. Disclaimer: This podcast is for informational purposes only and is not medical advice. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

KRAS Lung Cancer- Hope & The Future of Treatments with Dr Fawzi Abu Rous | Pt 3/3

he future of KRAS lung cancer treatment is moving fast ..here is what patients need to know about resistance, clinical trials, and emerging therapies, with thoracic oncologist Dr. Fawzi Abu Rous In the final part of the Young Lung Cancer Initiative KRAS Lung Cancer Biomarker Education Series, Dr. Fawzi Abu Rous of Henry Ford Cancer Institute walks us through the KRAS pipeline beyond G12C, how resistance develops on targeted therapy, and how patients can find clinical trials and stay informed over time. If you or a loved one is living with KRASnon-small cell lung cancer (NSCLC), this conversation is packed with practical next steps and a big dose of hope. KRAS is no longer undruggable. This episode is proudly sponsored by Revolution Medicines. About Young Lung Cancer Initiative (YLCI) The YLCI is a 501(c)(3) nonprofit dedicated to the young-onset community. We provide support, research, and advocacy to ensure that no young person faces a lung cancer diagnosis alone. Disclaimer: This podcast is for informational purposes only and is not medical advice. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

KRAS Lung Cancer Treatment & Monitoring with Dr Fawzi Abu Rous | Pt 2/3

In this episode, Dr. Fawzi Abu Rous provides a comprehensive overview of the treatment, monitoring, and progression of KRAS-driven lung cancer. The discussion covers the use of immunotherapy, targeted therapies, and the importance of clinical trials. Additionally, the role of monitoring and the emergence of new therapies are explored in detail. Takeaways * KRAS Treatment Overview * Monitoring and Progression in KRAS-Positive Lung Cancer Chapters * 00:00 Treatment for KRAS-Driven Lung Cancer * 05:49 Early Stage Treatment and Monitoring * 15:37 Monitoring and Clinical Trials This episode is proudly sponsored by Revolution Medicines. About Young Lung Cancer Initiative (YLCI) The YLCI is a 501(c)(3) nonprofit dedicated to the young-onset community. We provide support, research, and advocacy to ensure that no young person faces a lung cancer diagnosis alone. Disclaimer: This podcast is for informational purposes only and is not medical advice. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.